1. Generics Bulletin

Ontario Welcomes Biosimilar Switching Policy Following Extended Campaign

Industry Has Urged Province To Implement Switching Policy For Over A Year

 
• By Chloe Kent

Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.

Ontario flag blowing in wind
Ontario is the eight Canadian jurisdiction to implement a biosimilar switching policy • Source: Shutterstock

Ontario has become the seventh province – and eighth jurisdiction – in Canada to implement a biosimilar switching policy, with Ontario Drug Benefit recipients taking originator biologics now due to transition to biosimilar versions starting 31 March 2023.

Sylvia Jones, Ontario’s deputy premier and minister of health, said: “Ontario is joining other provinces and territories in the country by expanding the use of safe and effective biosimilar drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Generics Bulletin Explains: The Landscape For Denosumab Biosimilar Competition

 
• By Dave Wallace

One of the biggest biologic loss-of-exclusivity opportunities of the year is almost upon us, as biosimilars developers across the world get ready to launch rivals to Amgen’s denosumab brands Prolia and Xgeva. Generics Bulletin offers a rundown of some of the major contenders and how they view the market.

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By Dave Wallace

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.